MedTrace Logo

Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)

NCT02599961 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-06-11

Study results available
· View outcomes & findings →

Summary

The primary objective of the study is to evaluate the long-term safety of UX007 in Glut1 DS participants.

Conditions

  • Glucose Transporter Type 1 Deficiency Syndrome

Interventions

DRUG

UX007

UX007 is a liquid intended for oral (PO) administration.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Ultragenyx Pharmaceutical Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-10
Primary Completion
2019-10-22
Completion
2019-10-22

Countries

  • United States
  • Australia
  • Denmark
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02599961 on ClinicalTrials.gov